CAMBRIDGE, Mass., Feb. 27, 2014 /PRNewswire/ -- Epizyme, Inc. /quotes/zigman/15507302/delayed/quotes/nls/epzm EPZM +2.29% , a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced 2013 operating and financial results and provided 2014 guidance.
Help employers find you! Check out all the jobs and post your resume.
